Skip to Main Content

Paper Details

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Oral Oncol
1
2023
Author NameAffiliation
Ramona F SwabyMerck & Co., Inc.
  • 1 - 1

Datasets

Release 1.2